A favorable conclusion should be checked against the exact outcome comparisons. This NAD+ study reported a mixed pattern rather than a demonstrated clinical benefit. Primary study
What was studied
The single-center randomized, double-blind study compared short-course NAD+ with saline alongside standard heart-failure treatment. Sixty patients were enrolled and 58 analyzed. Between-group improvement-rate comparisons for NT-proBNP and ejection fraction were not significant. Other biomarker analyses, including an NT-proBNP trajectory analysis, reported differences. One-year clinical outcomes did not significantly differ. Registration was retrospective. Primary report
Our appraisal: different analyses answer different questions
A change trajectory, an improvement rate at a visit, and a clinical event rate are not the same endpoint. A significant result in one analysis cannot be used to relabel neutral comparisons in another. Conversely, reporting only the neutral comparisons would omit the study's exploratory biochemical findings.
The clinical question is whether adding the intervention improves outcomes that matter to patients. Biomarker changes can support a development hypothesis, but they cannot substitute for demonstrated reductions in hospitalization, mortality, or symptom burden.
Small samples also create uncertainty in both directions. A nonsignificant event comparison does not establish equivalence, and numerical differences should not become promises of benefit. The number of events and the precision of the effect estimate matter more than the direction of a percentage alone.
Retrospective registration makes it harder to verify which analyses were planned before results were known. That is a transparency limitation, not proof of misconduct. Exclusions after enrollment and inconsistencies in reported participant details also warrant careful review before quantitative claims are reused.
The appropriate interpretation is a small pilot with mixed biomarker evidence and no established advantage on the reported clinical comparisons. It does not validate NAD+ as heart-failure treatment or justify replacing established therapy. A positive narrative conclusion cannot remove the uncertainty in the underlying results.
Frequently asked questions
Was this randomized and blinded?
It was reported as randomized and double blind.
How many patients were analyzed?
Fifty-eight.
Were primary improvement-rate comparisons significant?
No.
Were all biomarker analyses neutral?
No, some reported differences.
Was one-year clinical benefit established?
No.
Was registration prospective?
No, it was retrospective.
What is the main takeaway?
Mixed pilot findings do not establish clinical efficacy.